Bright Minds Biosciences Inc. (DRUG)
Nasdaq: DRUG · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020
Income statement, as filed
In Canadian dollars (CAD), as filed; per-share figures in Canadian dollars; share counts. The fiscal year ends in September.The Form 40-F filed Dec 23, 2025 for the period ended Sep 30, 2025 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
| Report filed | Dec 23, 2025 | Dec 31, 2024 | Dec 29, 2023 | Dec 29, 2022 | Dec 29, 2021 | · | · |
| Research and development | 11,084,509 | 1,180,010 | 4,999,944 | 12,180,938 | 6,313,988 | 354,852 | · |
| Sales and marketing | 429,659 | 41,600 | 119,418 | 551,864 | 852,151 | 9,618 | · |
| General and administrative | 784,078 | 264,009 | 278,809 | 478,248 | 197,125 | 637 | · |
| Interest income | 1,519,468 | 30,133 | 0 | 0 | · | · | · |
| Income tax expense | · | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -12,229,348 | -2,801,946 | -7,372,225 | -14,964,941 | -8,650,763 | -480,377 | · |
| Earnings per share, basic | -1.78 | -0.65 | -1.98 | -6.06 | -4.82 | · | · |
| Earnings per share, diluted | · | -0.65 | -1.98 | -6.06r | -4.82r | -0.65b | · |
| Earnings per share, basic and diluted | · | · | · | · | -4.80b | -0.65b | · |
| Weighted average shares, basic | 6,878,051 | 4,310,168 | 3,719,775 | 2,470,383r | 1,794,805r | 722,487b | · |
| Weighted average shares, diluted | · | 4,310,168 | 3,719,775 | 2,470,383 | 1,794,805 | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-5 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
ifrs-full:SalesAndMarketingExpenseGeneral and administrative the cost of running the company itself
ifrs-full:GeneralAndAdministrativeExpenseInterest income what its cash and investments earned
ifrs-full:RevenueFromInterestIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareEarnings per share, basic and diluted net income per share, where both counts are the same
ifrs-full:BasicAndDilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares